Latest Financial Results

Q3 2018

Quarterly Results

Ended Jul 31, 2018

Stock Information

Symbol

ANIX

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

By using the body's immune system, Anixa Biosciences is taking multiple approaches to fighting cancer-developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. Anixa is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Anixa is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.

Logo Itus

Latest News & Events

Anixa Biosciences Files Pre-Submission and Requests Meeting with FDA Regarding Cchek™ Artificial Intelligence based Cancer Detection Technology

Read More...

Anixa Biosciences Appoints Leading Researchers in Immuno-Oncology to its Scientific Advisory Board

Read More...

Anixa Biosciences to Present at Artificial Intelligence Conference

Read More...

Cancer Fact: Approximately 40 million mammograms are conducted annually.